ERCP After Liver Transplant

Liver transplantation replaces a failing liver with a donor organ and is typically pursued when disease-modifying treatments can no longer prevent life-threatening complications of cirrhosis, liver failure, or selected liver cancers. ERCP is a specialized endoscopic procedure that visualizes the bile duct and pancreatic duct using contrast injection and fluoroscopy, enabling clinicians to diagnose and treat obstruction, leaks, strictures, and infection. In transplant medicine, ERCP’s value is its combined diagnostic and therapeutic capability—often allowing timely intervention without surgical revision. ^{[1] [2] [5]}

Biliary complications are among the most common technical complications after liver transplantation and include bile leaks, anastomotic strictures, and non-anastomotic strictures. These problems can present with cholestatic lab abnormalities, jaundice, fever, right upper quadrant pain, or recurrent cholangitis, and they may threaten graft function if diagnosis or treatment is delayed. In many transplant pathways, noninvasive imaging (ultrasound, MRCP) is a first step, but direct cholangiography remains a definitive diagnostic modality, and ERCP frequently provides the therapeutic endpoint. ^{[5] [6] [7]}

ERCP is generally performed when clinicians suspect biliary obstruction or injury and believe endoscopic therapy may correct it. Post-transplant indications commonly include suspected anastomotic stricture, bile leak (anastomosis, T-tube site, cystic duct remnant), bile duct stones/sludge, cholangitis, and evaluation of ductal abnormalities when imaging suggests a correctable lesion. Tissue sampling may be performed when malignancy or alternative etiologies are considered. In certain surgical anatomies (e.g., Roux-en-Y), ERCP may be technically limited and alternative approaches may be required. ^{[3] [4] [5]}

Note: Specific device selection and sequencing vary by center protocol, anatomy, and complication type. ^{[4] [5]}

Preparation typically includes fasting so the stomach and duodenum are empty, review of anticoagulants/antiplatelets, allergy history (contrast reactions are uncommon but relevant), and assessment of cardiopulmonary risk for sedation or anesthesia. In transplant recipients, teams also review infection risk, immunosuppression timing, and current labs (bilirubin trend, INR/platelets if interventions such as sphincterotomy are anticipated). The endoscopy team will explain expected benefits, alternatives, and complication risks in consent. ^{[2] [9]}

Under sedation or anesthesia, an endoscope is advanced through the mouth into the duodenum, where the papilla is cannulated. Contrast dye is injected into the bile duct and/or pancreatic duct under fluoroscopy to define ductal anatomy and identify strictures, leaks, stones, or filling defects. If pathology is found, therapeutic steps can often be performed immediately (dilation, stent placement, stone extraction, sampling). Procedure complexity varies; post-transplant ERCP can be technically more challenging depending on anatomy and duct size mismatch. ^{[5] [7]}

ERCP is not just diagnostic. Common therapeutic maneuvers include biliary sphincterotomy (selected cases), balloon dilation of strictures, placement of plastic stents (often serial exchanges for anastomotic strictures), fully-covered self-expanding metal stents in selected scenarios, and extraction of stones or sludge with baskets/balloons. Brush cytology, biopsies, and bile cultures may be obtained when clinicians need to clarify whether ductal abnormalities reflect benign stricture, infection, ischemic injury, or malignancy. These endoscopic interventions are central to modern management of post-transplant biliary complications. ^{[4] [5]}

ERCP is generally safe, but complications can occur. The most common serious adverse event is post-ERCP pancreatitis (PEP). Other potential adverse events include bleeding (often post-sphincterotomy), infection/cholangitis, cardiopulmonary events related to sedation, and rare perforation. In transplant recipients, risk is influenced by procedure complexity, anatomy, and patient factors, and complications can have higher downstream impact due to immunosuppression. Early recognition and prompt management are critical to reducing morbidity. ^{[9] [10] [5]}

Current gastroenterology guidelines support preventive strategies for PEP in appropriate patients, including use of rectal nonsteroidal anti-inflammatory drugs (NSAIDs) such as indomethacin/diclofenac (when not contraindicated) and prophylactic pancreatic duct stenting for high-risk cases. Additional measures may be selected based on risk profile and intra-procedural events. Prevention is individualized, particularly in patients with renal dysfunction, bleeding risk, or contraindications to NSAIDs. ^{[11] [12]}

Note: The expected risk profile varies by indication, patient factors, and the type of intervention performed during ERCP. ^{[9] [11]}

After ERCP, patients may experience transient sore throat, bloating, or mild discomfort. Your transplant and endoscopy teams will advise when to restart diet and medications, and whether follow-up labs or imaging are needed. Because transplant recipients are immunosuppressed, clinicians maintain a low threshold to evaluate fever or abdominal pain after ERCP. If a stent is placed, planned follow-up for exchange/removal is essential to avoid occlusion and infection. Your team will provide individualized timelines and warning signs. ^{[5] [9]}

1. NIDDK — Liver Transplant (overview and indications)
2. MedlinePlus — ERCP (procedure overview)
3. Verdonk et al. — Biliary complications after liver transplantation: a review (2006)
4. Kochhar et al. — Biliary complications following liver transplantation (World J Gastroenterol, 2013)
5. Magro et al. — Biliary complications after liver transplantation (World J Gastroenterol, 2021; PMC)
6. Seehofer et al. — Biliary Complications After Liver Transplantation (2013 review)
7. Ryu et al. — Biliary strictures after liver transplantation (Gut and Liver, 2011)
8. AASLD Liver Fellow Network — Differential for abnormal labs after transplant (clinical pearls)
9. ASGE — Adverse events associated with ERCP (Gastrointest Endosc, 2017)
10. ASGE Guidelines portal — ERCP adverse events (summary page)
11. ASGE Guideline — Post-ERCP pancreatitis prevention strategies (Summary, 2023)
12. ASGE Guideline — Post-ERCP pancreatitis prevention strategies (Methodology, 2023)